{"classes":[{"categories":[{"measurements":[{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"3.68","upperLimit":"NA","value":"7.26"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"1.64","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG004","lowerLimit":"3.52","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG005","lowerLimit":"NA","upperLimit":"NA","value":"5.75"},{"groupId":"OG006","lowerLimit":"3.68","upperLimit":"13.73","value":"5.49"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG007","lowerLimit":"1.68","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG008","lowerLimit":"1.74","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG009","lowerLimit":"2.33","upperLimit":"NA","value":"NA"},{"comment":"N/A=NE=not estimable due to insufficient number of participants with events","groupId":"OG010","lowerLimit":"3.68","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"27"},{"groupId":"OG004","value":"9"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"26"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"12"},{"groupId":"OG009","value":"9"},{"groupId":"OG010","value":"28"}],"units":"Participants"}],"description":"Time to response was defined as the time from the first day of study treatment to the date of first CR, or PR for solid tumors according to RECISTv1.1 and CR, PR, VGPR or sCR for multiple myeloma according to IMWG criteria. RECIST v1.1: CR: disappearance of all target lesions; PR: at least a 30% decrease in the sum of diameters of target lesions. IMWG criteria: CR: negative immunofixation on serum and urine and disappearance of any soft tissue plasmacytomas and \\</= 5% plasma cells in bone marrow; PR: \\>/= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>/= 90% or to \\< 200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>/= 90% reduction in serum M-protein plus urine M-protein level \\< 100 mg per 24 hour; sCR: CR plus normal FLC ratio and no clonal cells in bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with NSCLC were treated with vemurafenib monotherapy.","id":"OG000","title":"Cohort 1: Non-Small Cell Lung Cancer (NSCLC) - Vemurafenib"},{"description":"Participants with ovarian cancer were treated with vemurafenib monotherapy.","id":"OG001","title":"Cohort 2: Ovarian Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib monotherapy.","id":"OG002","title":"Cohort 3a: Colorectal Cancer - Vemurafenib"},{"description":"Participants with colorectal cancer were treated with vemurafenib and cetuximab combination therapy.","id":"OG003","title":"Cohort 3b: Colorectal Cancer - Vemurafenib + Cetuximab"},{"description":"Participants with cholangiocarcinoma were treated with vemurafenib monotherapy.","id":"OG004","title":"Cohort 4: Cholangiocarcinoma - Vemurafenib"},{"description":"Participants with multiple myeloma were treated with vemurafenib monotherapy.","id":"OG005","title":"Cohort 6: Multiple Myeloma - Vemurafenib"},{"description":"Participants with Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH) were treated with vemurafenib monotherapy.","id":"OG006","title":"Cohort 7a: ECD/LCH - Vemurafenib"},{"description":"Participants with anaplastic thyroid cancer were treated with vemurafenib monotherapy.","id":"OG007","title":"Cohort 7b: Anaplastic Thyroid Cancer - Vemurafenib"},{"description":"Participants with advanced stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG008","title":"Cohort 7c: Advanced Stage Astrocytoma - Vemurafenib"},{"description":"Participants with early stage astrocytoma were treated with vemurafenib monotherapy.","id":"OG009","title":"Cohort 7d: Early Stage Astrocytoma - Vemurafenib"},{"description":"Participants with other BRAF V600-positive tumors were treated with vemurafenib monotherapy.","id":"OG010","title":"Cohort 7: Other BRAF V600-positive Tumors - Vemurafenib"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants enrolled in the study irrespective of whether they had received study medication or not.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}